US Patent

US11752198 — GLP-1 compositions and uses thereof

Method of Use · Assigned to Novo Nordisk AS · Expires 2038-08-24 · 12y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical compositions of the GLP-1 peptide semaglutide with no more than 0.01% phenol content.

USPTO Abstract

The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.01% (w/w) phenol, their preparation, kits comprising such compositions as well as uses thereof.

Drugs covered by this patent

Ozempic (semaglutide) · Novo Nordisk

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4418`	—	Ozempic
`U-3162`	—	Ozempic
`U-3162`	—	Ozempic
`U-3162`	—	Ozempic
`U-3162`	—	Ozempic
`U-3162`	—	Ozempic

Patent Metadata

Patent number: US11752198
Jurisdiction: US
Classification: Method of Use
Expires: 2038-08-24
Drug substance claim: No
Drug product claim: Yes
Assignee: Novo Nordisk AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.